



KDIGO CKD-MBD GUIDELINE UPDATE

Recommendation Statements for Implementation

3.1.1: We recommend monitoring serum levels of calcium, phosphate, PTH, and alkaline phosphatase activity beginning in CKD ~~G3a~~ G3b* (1C). **focus on G3b for this meeting*

4.1.3: In adult patients with CKD G3a– G5D, we suggest avoiding hypercalcemia (2C).

4.1.6: In adult patients with CKD G3a– G5D receiving phosphate-lowering treatment, we suggest restricting the dose of calcium-based phosphate binders (2B).

4.1.7: In patients with CKD G3a-G5D, we recommend avoiding the long-term use of aluminum-containing phosphate binders and, in patients with CKD G5D, avoiding dialysate aluminum contamination to prevent aluminum intoxication (1C).

4.2.4: In patients with CKD G5D requiring PTH-lowering therapy, we suggest calcimimetics, calcitriol, or vitamin D analogs, or a combination of calcimimetics with calcitriol or vitamin D analogs (2B).